Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00060944 · ClinicalTrials.gov registry record · Phase 2
A Study to Assess Treatment With 2 Different Dosing Schedules of Trabectidin Administered to Patients With Advanced Cancer
A Phase 2 study, sponsored by Johnson & Johnson Pharmaceutical Research & Development, L.L.C..
- Completed
- Registry status
- Phase 2
- Development phase
- 271
- Enrollment target
NCT00060944: Completed Phase 2 study, sponsored by Johnson & Johnson Pharmaceutical Research & Development, L.L.C..
NCT00060944 is a Phase 2 study that has completed, run by Johnson & Johnson Pharmaceutical Research & Development, L.L.C.. The registered enrollment target is 271 participants, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (104% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00060944, a Phase 2 study, has completed, sponsored by Johnson & Johnson Pharmaceutical Research & Development, L.L.C..
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 271 participants
- Enrollment target
Study Summary
The purpose of this study is to test the safety and effectiveness of an investigational chemotherapy agent in patients with types of advanced cancer referred to as liposarcoma or leiomyosarcoma.
Primary Outcome
Time to Progression was defined as time between randomization and the first documentation of disease progression or death due to progressive disease.
Interventions
- DRUG Dexamethasone
- DRUG Yondelis
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 271 participants |
| Start Date | 2003-05 |
| Est. Completion | 2008-05 |
| Phase | Phase 2 |
What the finished NCT00060944 record still lists
NCT00060944 is an interventional study that assigns participants to a tested intervention. The registered 271 participants enrollment target is mid-sized for trials with a published cap, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (104% higher).
The record links to 0 conditions, and to 2 interventions - of which Dexamethasone is the first listed.
NCT00060944 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00060944 about?
NCT00060944 is a clinical study titled "A Study to Assess Treatment With 2 Different Dosing Schedules of Trabectidin Administered to Patients With Advanced Cancer". The purpose of this study is to test the safety and effectiveness of an investigational chemotherapy agent in patients with types of advanced cancer referred to as liposarcoma or leiomyosarcoma.
What is the current status of trial NCT00060944?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 271 participants. The study started on 2003-05. Estimated completion is 2008-05.
What interventions are being tested in trial NCT00060944?
The interventions under investigation include: Dexamethasone (DRUG), Yondelis (DRUG).
Who is sponsoring clinical trial NCT00060944?
This trial is sponsored by Johnson & Johnson Pharmaceutical Research & Development, L.L.C., which has 102 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00060944's enrollment target sits among peer trials
271 205th of 2000 higher than 1,796 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03609216 · 271 participants · Phase 2
Gemcitabine and Cisplatin Without Cystectomy for Patients With Muscle Invasive Bladder Urothelial Cancer and Select Genetic Alterations
- NCT02468024 · 272 participants · Phase 3
JoLT-Ca Sublobar Resection (SR) Versus Stereotactic Ablative Radiotherapy (SAbR) for Lung Cancer
- NCT05519449 · 272 participants · Phase 1
Study of JANX007 in Subjects With Metastatic Castration-Resistant Prostate Cancer (ENGAGER-PSMA-01)
- NCT06035939 · 272 participants · NA
SMYLS Multi-site Trial
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia